SciSparc Shares Skyrocket With AutoMax's First JAC Motors Shipment
SciSparc Shares Skyrocket With AutoMax's First JAC Motors Shipment
SciSparc has provided financial support to AutoMax, enabling the resources necessary to facilitate the JAC Motors transaction.SciSparc Ltd. (NASDAQ:SPRC) shares are rocketing on Thursday after it disclosed that AutoMax Motors Ltd., an Israeli automotive importer and distributor with which it has a merger agreement, has received its $13 million first delivery of JAC vehicles from Anhui Jianghuai Automobile Group Co., Ltd. (JAC Motors).
ScisPARC Ltd.（纳斯达克股票代码：SPRC）周四股价飙升，此前该公司透露，与其签订合并协议的以色列汽车进口商和分销商AutoMax Motors有限公司已从安徽江淮汽车集团有限公司（JAC Motors）收到首批1300万美元的江淮汽车。
This marks a key milestone in AutoMax's direct import and distribution operations initiated earlier this year under agreements with JAC Motors.
这标志着AutoMAX根据与江淮汽车的协议于今年早些时候启动的直接进口和分销业务的关键里程碑。
With regulatory approvals in place, AutoMax is set to begin marketing and sales activities for JAC Motors vehicles across Israel.
获得监管部门批准后，AutoMAX将开始在以色列各地为江淮汽车的营销和销售活动。
SciSparc has provided financial support to AutoMax, enabling the resources necessary to facilitate the JAC Motors transaction.
ScisPARC为AutoMax提供了财务支持，为促进江淮汽车的交易提供了必要的资源。
As part of its growth strategy, SciSparc entered into a merger agreement with AutoMax in April 2024.
作为其增长战略的一部分，ScisPARC于2024年4月与AutoMax签订了合并协议。
If completed, this merger would expand SciSparc into the automotive sector, subject to shareholder approval and other closing conditions.
如果完成，此次合并将把ScisPARC扩展到汽车行业，但须获得股东批准和其他成交条件。
This month, SciSparc disclosed an amendment to its non-binding letter of intent (LOI) regarding the spin-off of its advanced clinical-stage pharmaceutical portfolio and equity stake in SciSparc Nutraceuticals Inc.
本月，ScisPARC披露了其不具约束力的意向书（LOI）的修正案，内容涉及分拆其先进临床阶段的药物投资组合和ScisPARC Nutraceuticals Inc的股权。
Price Action: SPRC shares are trading higher by 256% at $0.7874 premarket at the last check Thursday.
价格走势：在周四的最后一次支票中，SPRC股票盘前交易价格上涨256％，至0.7874美元。
Read Next:
继续阅读：
- Pharma Company Gets FDA Green Light For Next Phase Trial For Tourette Syndrome
- 制药公司获得美国食品药品管理局对图雷特综合症下一阶段试验的批准
Image via Shutterstock.
图片来自 Shutterstock。
